What is Medical Prop's earnings per share (EPS)?

Medical Prop (MPW) reported diluted earnings per share of $-0.46 for fiscal year 2025. This represents a 88.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Medical Prop Financials

MPW

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Medical Prop (MPW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MPW FY2025 2026-04-22

Equity erosion, not fresh borrowing, is pushing leverage higher while the business throws off less operating cash from its asset base.

From FY2022 to FY2025, debt-to-equity climbed from 1.2x to 2.1x. Long-term debt ended FY2025 at $9.7B against equity of $4.6B, so the balance sheet tightened mostly because repeated losses shrank the capital cushion over time, not because debt suddenly surged.

Gross margin stayed extremely high at 90.7%, which suggests the underlying assets still bring in revenue with relatively little direct cost. The squeeze sits in financing: interest expense was $510M while operating cash flow was only $231M, so the capital structure absorbed more cash than operations produced.

Since FY2021, total assets have shrunk from $20.5B to $15.0B. With revenue still below $1.0B, the company is earning on a meaningfully smaller asset base, so each turn of deleveraging also trims the pool of available cash-producing assets.

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Medical Prop's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Growth

Medical Prop's revenue declined 2.4% year-over-year, from $995.5M to $972.0M. This contraction results in a growth score of 43/100.

Leverage

Medical Prop has a moderate D/E ratio of 2.11. This balance of debt and equity financing earns a leverage score of 59/100.

Returns

Medical Prop generates a -6.0% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -49.9% the prior year.

Piotroski F-Score Neutral

4/9

Medical Prop passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Mixed

-0.83x

For every $1 of reported earnings, Medical Prop generates $-0.83 in operating cash flow ($230.8M OCF vs -$277.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$972.0M

YoY-2.4%

5Y CAGR-4.9%

10Y CAGR+8.2%

Medical Prop generated $972.0M in revenue in fiscal year 2025. This represents a decrease of 2.4% from the prior year.

EBITDA

N/A

Net Income

-$277.0M

YoY+88.5%

Medical Prop reported -$277.0M in net income in fiscal year 2025. This represents an increase of 88.5% from the prior year.

EPS (Diluted)

$-0.46

YoY+88.6%

Medical Prop earned $-0.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 88.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$540.9M

YoY+62.7%

5Y CAGR-0.3%

10Y CAGR+10.7%

Medical Prop held $540.9M in cash against $9.7B in long-term debt as of fiscal year 2025.

Dividends Per Share

$0.33

YoY-28.3%

5Y CAGR-21.1%

10Y CAGR-9.3%

Medical Prop paid $0.33 per share in dividends in fiscal year 2025. This represents a decrease of 28.3% from the prior year.

Shares Outstanding

597M

YoY-0.6%

5Y CAGR+2.0%

10Y CAGR+9.7%

Medical Prop had 597M shares outstanding in fiscal year 2025. This represents a decrease of 0.6% from the prior year.

Margins & Returns

Gross Margin

90.7%

YoY-1.8pp

5Y CAGR-6.9pp

Medical Prop's gross margin was 90.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.8 percentage points from the prior year.

Operating Margin

N/A

Net Margin

-28.5%

YoY+213.6pp

5Y CAGR-63.0pp

10Y CAGR-60.1pp

Medical Prop's net profit margin was -28.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 213.6 percentage points from the prior year.

Return on Equity

-6.0%

YoY+43.9pp

5Y CAGR-11.9pp

10Y CAGR-12.7pp

Medical Prop's ROE was -6.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 43.9 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

$23.4M

Medical Prop spent $23.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

MPW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$972.0M-2.4%	$995.5M+14.2%	$871.8M-43.5%	$1.5B-0.1%	$1.5B+23.6%	$1.2B
Cost of Revenue	$90.3M+21.8%	$74.2M-32.6%	$110.1M-34.3%	$167.4M+65.0%	$101.4M+236.6%	$30.1M
Gross Profit	$881.7M-4.3%	$921.4M+21.0%	$761.7M-44.6%	$1.4B-4.7%	$1.4B+18.4%	$1.2B
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$130.4M-2.5%	$133.8M-8.1%	$145.6M-9.3%	$160.5M+10.2%	$145.6M+10.6%	$131.7M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$510.4M+22.1%	$417.8M+1.6%	$411.2M+14.5%	$359.0M-2.3%	$367.4M+11.8%	$328.7M
Income Tax	$38.6M-12.4%	$44.1M+133.7%	-$130.7M-333.8%	$55.9M-24.4%	$73.9M+138.1%	$31.1M
Net Income	-$277.0M+88.5%	-$2.4B-333.1%	-$556.5M-161.7%	$902.6M+37.6%	$656.0M+52.0%	$431.4M
EPS (Diluted)	$-0.46+88.6%	$-4.02-332.3%	$-0.93-162.0%	$1.50+35.1%	$1.11+37.0%	$0.81

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$252.1M-6.8%	$270.3M+13.8%	$237.5M-1.2%	$240.4M+7.4%	$223.8M-3.5%	$231.8M+2.7%	$225.8M-15.3%	$266.6M
Cost of Revenue	$97.3M	N/A	N/A	N/A	$81.4M	N/A	N/A	N/A
Gross Profit	$154.7M	N/A	N/A	N/A	$142.4M	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$32.2M+31.0%	$24.6M-34.8%	$37.7M+44.0%	$26.2M-37.5%	$41.9M+47.1%	$28.5M-22.2%	$36.6M+3.7%	$35.3M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$133.3M+0.7%	$132.5M0.0%	$132.4M+2.1%	$129.7M+12.0%	$115.8M+14.1%	$101.5M-4.5%	$106.2M+4.7%	$101.4M
Income Tax	-$32.8M-485.9%	$8.5M-21.8%	$10.9M+10.9%	$9.8M+3.9%	$9.4M-1.3%	$9.6M+5.9%	$9.0M-38.0%	$14.6M
Net Income	$32.8M+89.1%	$17.4M+122.3%	-$77.7M+21.0%	-$98.4M+16.8%	-$118.3M+71.4%	-$412.9M+48.5%	-$801.2M-149.9%	-$320.6M
EPS (Diluted)	$0.05	N/A	$-0.13+18.8%	$-0.16+20.0%	$-0.20	N/A	$-1.34-148.1%	$-0.54

MPW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$15.0B+4.9%	$14.3B-21.9%	$18.3B-6.9%	$19.7B-4.2%	$20.5B+21.9%	$16.8B
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$540.9M+62.7%	$332.3M+32.9%	$250.0M+6.1%	$235.7M-48.7%	$459.2M-16.5%	$549.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.4B+9.9%	$9.5B-11.3%	$10.7B-3.5%	$11.1B-8.4%	$12.1B+27.3%	$9.5B
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	$9.7B+9.6%	$8.8B-12.1%	$10.1B-2.0%	$10.3B-9.0%	$11.3B+27.3%	$8.9B
Total Equity	$4.6B-4.7%	$4.8B-36.7%	$7.6B-11.2%	$8.6B+1.8%	$8.4B+15.0%	$7.3B
Retained Earnings	-$4.1B-13.1%	-$3.7B-276.5%	-$971.8M-935.7%	$116.3M+232.6%	-$87.7M-22.8%	-$71.4M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$14.8B-1.6%	$15.0B+0.5%	$14.9B-1.5%	$15.2B+2.0%	$14.9B+3.9%	$14.3B-6.2%	$15.2B-5.9%	$16.2B
Current Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cash & Equivalents	$425.0M-21.4%	$540.9M+36.4%	$396.6M-22.2%	$509.8M-24.3%	$673.5M+102.7%	$332.3M+20.6%	$275.6M-54.6%	$606.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.2B-1.7%	$10.4B+1.3%	$10.3B-0.5%	$10.3B+2.2%	$10.1B+6.7%	$9.5B-3.4%	$9.8B-2.1%	$10.0B
Current Liabilities	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Debt	$9.7B-0.4%	$9.7B+0.8%	$9.6B-0.3%	$9.6B+1.9%	$9.5B+7.0%	$8.8B-4.0%	$9.2B-1.6%	$9.4B
Total Equity	$4.5B-1.3%	$4.6B-1.2%	$4.7B-3.6%	$4.8B+1.5%	$4.8B-1.5%	$4.8B-11.1%	$5.4B-12.1%	$6.2B
Retained Earnings	-$4.2B-0.5%	-$4.1B-0.9%	-$4.1B-3.2%	-$4.0B-3.8%	-$3.8B-4.6%	-$3.7B-14.4%	-$3.2B-36.2%	-$2.3B

MPW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$230.8M-6.0%	$245.5M-51.5%	$505.8M-31.6%	$739.0M-9.0%	$811.7M+31.4%	$617.6M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$264.7M-120.1%	$1.3B+154.7%	$517.6M+30.7%	$396.1M+110.3%	-$3.9B-30.9%	-$2.9B
Financing Cash Flow	$228.1M+115.4%	-$1.5B-45.0%	-$1.0B+24.0%	-$1.3B-145.5%	$2.9B+110.4%	$1.4B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$23.4M	N/A	N/A	$17.9M	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$14.3M-108.9%	$160.1M+761.9%	$18.6M-64.1%	$51.7M+13375.8%	$384K-99.5%	$76.7M+29.5%	$59.2M+67.9%	$35.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$76.8M-875.7%	-$7.9M+91.7%	-$95.1M-31.6%	-$72.3M+19.1%	-$89.4M-197.5%	$91.7M-36.2%	$143.8M-88.0%	$1.2B
Financing Cash Flow	-$23.2M-158.5%	-$9.0M+73.9%	-$34.5M+77.7%	-$154.8M-136.3%	$426.3M+527.2%	-$99.8M+81.8%	-$548.1M+35.8%	-$853.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MPW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	90.7%-1.8pp	92.5%+5.2pp	87.4%-1.8pp	89.1%-4.3pp	93.4%-4.2pp	97.6%
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-28.5%+213.6pp	-242.1%-178.3pp	-63.8%-122.3pp	58.5%+16.0pp	42.5%+7.9pp	34.5%
Return on Equity	-6.0%+43.9pp	-49.9%-42.6pp	-7.3%-17.8pp	10.5%+2.7pp	7.8%+1.9pp	5.9%
Return on Assets	-1.8%+15.0pp	-16.9%-13.8pp	-3.0%-7.6pp	4.6%+1.4pp	3.2%+0.6pp	2.6%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	2.11+0.3	1.83+0.5	1.32+0.1	1.20-0.1	1.34+0.1	1.21
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	61.4%	N/A	N/A	N/A	63.6%	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	13.0%+6.6pp	6.4%+39.1pp	-32.7%+8.2pp	-40.9%+11.9pp	-52.8%+125.2pp	-178.1%+176.7pp	-354.8%-234.5pp	-120.3%
Return on Equity	0.7%+0.3pp	0.4%+2.1pp	-1.7%+0.4pp	-2.0%+0.4pp	-2.5%+6.1pp	-8.5%+6.2pp	-14.7%-9.5pp	-5.2%
Return on Assets	0.2%+0.1pp	0.1%+0.6pp	-0.5%+0.1pp	-0.7%+0.2pp	-0.8%+2.1pp	-2.9%+2.4pp	-5.3%-3.3pp	-2.0%
Current Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Debt-to-Equity	2.13+0.0	2.11+0.0	2.06+0.1	2.000.0	1.99+0.2	1.83+0.1	1.69+0.2	1.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

National Health Investors NHI

$3.7B

Sabra Health Care Reit Inc SBRA

$5.2B

Caretrust CTRE

$9.7B

Healthcare Tr Amer Inc HR

$7.1B

AMERICAN HEALTHCARE REIT INC AHR

$9.7B

Frequently Asked Questions

What is Medical Prop's annual revenue?

Medical Prop (MPW) reported $972.0M in total revenue for fiscal year 2025. This represents a -2.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Medical Prop's revenue growing?

Medical Prop (MPW) revenue declined by 2.4% year-over-year, from $995.5M to $972.0M in fiscal year 2025.

Is Medical Prop profitable?

No, Medical Prop (MPW) reported a net income of -$277.0M in fiscal year 2025, with a net profit margin of -28.5%.

How much debt does Medical Prop have?

As of fiscal year 2025, Medical Prop (MPW) had $540.9M in cash and equivalents against $9.7B in long-term debt.

What is Medical Prop's gross margin?

Medical Prop (MPW) had a gross margin of 90.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Medical Prop's net profit margin?

Medical Prop (MPW) had a net profit margin of -28.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Medical Prop pay dividends?

Yes, Medical Prop (MPW) paid $0.33 per share in dividends during fiscal year 2025.

What is Medical Prop's return on equity (ROE)?

Medical Prop (MPW) has a return on equity of -6.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Medical Prop's operating cash flow?

Medical Prop (MPW) generated $230.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Medical Prop's total assets?

Medical Prop (MPW) had $15.0B in total assets as of fiscal year 2025, including both current and long-term assets.

Does Medical Prop buy back shares?

Yes, Medical Prop (MPW) spent $23.4M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Medical Prop have outstanding?

Medical Prop (MPW) had 597M shares outstanding as of fiscal year 2025.

What is Medical Prop's debt-to-equity ratio?

Medical Prop (MPW) had a debt-to-equity ratio of 2.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Medical Prop's return on assets (ROA)?

Medical Prop (MPW) had a return on assets of -1.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Medical Prop's Piotroski F-Score?

Medical Prop (MPW) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Medical Prop's earnings high quality?

Medical Prop (MPW) has an earnings quality ratio of -0.83x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Medical Prop?

Medical Prop (MPW) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.